Pharmaceutical Technology4h
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA
The EMA CHMP has recommended granting approval for AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis ...
Pharmaceutical Technology4h
Takeda’s FRUZAQLA approved in Japan for advanced colorectal cancer
Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer ...
Pharmaceutical Technology6h
EC authorises LEO Pharma Anzupgo cream for chronic hand eczema
The EC has granted marketing authorisation to LEO Pharma’s Anzupgo cream for treating adults with moderate to severe chronic ...
Pharmaceutical Technology6h
FDA approves UCB’s BIMZELX for multiple inflammatory conditions
UCB has received US FDA approval for BIMZELX (bimekizumab-bkzx) to treat adults with three inflammatory conditions.
Pharmaceutical Technology17h
FDA approves AstraZeneca FluMist flu vaccine for self-administration
The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...
Pharmaceutical Technology23h
Ipsen’s Iqirvo wins European approval for primary biliary cholangitis
The European Commission (EC) has conditionally approved Ipsen ’s Iqirvo (elafibranor) for the treatment of primary biliary ...
Pharmaceutical Technology22h
Pancreatic cancer: The clinical trial landscape and progress for 2024
Pancreatic cancer is resistant to conventional therapies, but cutting-edge research may improve survival rates and patient ...
Pharmaceutical Technology20h
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.